Chelsea Counsel Company’s Prime Medicine PRME Stock Holding History

Chelsea Counsel Company’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.61M	Buy	462,340 +235,340	+104%	+$896K	0.72%	33
2025 Q4	$788K	Buy	227,000 +18,790	+9%	+$83.6K	0.34%	52
2025 Q3	$1.15M	Hold	208,210	–	–	0.51%	41
2025 Q2	$514K	Hold	208,210	–	–	0.26%	62
2025 Q1	$414K	Buy	208,210 +21,430	+11%	+$54.7K	0.23%	72
2024 Q4	$545K	Buy	186,780 +108,090	+137%	+$379K	0.28%	61
2024 Q3	$305K	Buy	78,690 +1,000	+1%	+$4.63K	0.15%	84
2024 Q2	$399K	Buy	77,690 +72,690	+1,454%	+$441K	0.2%	72
2024 Q1	$35K	Hold	5,000	–	–	0.02%	124
2023 Q4	$44.3K	Buy	5,000 +4,400	+733%	+$33.9K	0.02%	120
2023 Q3	$5.72K	Hold	600	–	–	﹤0.01%	158
2023 Q2	$8.79K	Hold	600	–	–	﹤0.01%	152
2023 Q1	$7.38K	Hold	600	–	–	﹤0.01%	143
2022 Q4	$11.1K	Buy	+600	New	+$10.8K	0.01%	147

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Chelsea Counsel Company's PRME Position: Q1 2026 in Review

Chelsea Counsel Company increased its Prime Medicine (PRME) stake by 104% in Q1 2026, buying an estimated $896K and bringing the position to 462,340 shares worth $1.61M. The position accounts for 0.72% of the portfolio, ranked #33.

Chelsea Counsel Company first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

Chelsea Counsel Company held 462,340 shares of Prime Medicine worth $1.61M as of Q1 2026.
Chelsea Counsel Company bought 235,340 Prime Medicine shares in Q1 2026, an estimated $896K.
Prime Medicine made up 0.72% of Chelsea Counsel Company's portfolio in Q1 2026, its #33 holding.
Chelsea Counsel Company first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Chelsea Counsel Company's 13F filing for Q1 2026, filed 24 Apr 2026.